At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 406 enrolled
Drug / intervention
S-600918 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in Patients With Refractory Chronic Cough
In Brief
A Phase 2 clinical trial evaluating S-600918 and Placebo to S-600918 for Chronic Cough. Completed, enrolled 406 participants across 136 sites in 6 countries.
Detailed Summary
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Cough
CountriesCzechia, Japan, Poland, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartFeb 2020
Primary CompletionDec 2020
Study CompletionDec 2020
TodayJul 2026
First PostedOct 1, 2019
Enrollment StartFeb 13, 2020
Primary CompletionDec 8, 2020
Study CompletionDec 28, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.8 years ago
Interventions
S-600918drug
Tablets for oral administration
Placebo to S-600918drug
Tablets for oral administration